Home / Private raises / Kura Oncology, Inc.
Kura Oncology, Inc.
Biotechnology · San Diego, California · $5.0M sold across 1 offering
Form D filings (1)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-11-18 | D (new) | $5.0M | $25.0M | 1 | 506(b) | Equity | Nov 9 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Issuer
| Industry | Biotechnology |
| Located | San Diego, California |
| Entity | Corporation |
| Incorporated | Delaware |
| SEC CIK | 1422143 |
People named in the latest filing
| Name | Role |
|---|---|
| Troy Wilson | Executive Officer, Director |
| Kathleen Ford | Executive Officer |
| Jennifer Fulk | Executive Officer |
| Francis Burrows | Executive Officer |
| Mollie Leoni | Executive Officer |
| Teresa Bair | Executive Officer |
| Brian Powl | Executive Officer |
| Faheem Hasnain | Director |
| Helen Collins | Director |
| Thomas Malley | Director |
| Diane Parks | Director |
| Carol Schafer | Director |
| Mary Szela | Director |
| Michael Vasconcelles | Director |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
